Effect on Patients’ Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization

BACKGROUND: Following addition of a biosimilar filgrastim product to the formulary, sites in the authors’ provincial health authority transitioned from using the originator filgrastim to the biosimilar for autologous stem cell mobilization. OBJECTIVE: To assess the effect on patient outcomes of a un...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Can J Hosp Pharm
Autors principals: Fenna, Jennifer, Guirguis, Micheal, Ibrahim, Caroline, Shirvaikar, Neeta, Sandhu, Irwindeep, Ghosh, Sunita, Jenkins, Melissa
Format: Artigo
Idioma:Inglês
Publicat: Canadian Society of Hospital Pharmacists 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8042197/
https://ncbi.nlm.nih.gov/pubmed/33896951
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars